• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Artificial Organs >Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation.
【24h】

Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation.

机译：血浆置换术和利妥昔单抗联合治疗肾移植术后复发性局灶性节段性肾小球硬化症。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Therapy for recurrent focal segmental glomerulosclerosis (FSGS) in the renal allograft is largely based on case reports. The use of plasmapheresis alone (based on its effectiveness in children) appears less effective in adults, reaching a response rate of <40%. Recently, rituximab, an anti-CD20 monoclonal chimeric antibody, showed promising results as rescue therapy in plasmapheresis-resistant recurrent FSGS. However, following rituximab administration, response is variable, often slow and consequently overlooked. We report a series of four cases of recurrent FSGS following renal transplantation successfully treated with a combination of plasmapheresis and rituximab. Complete remission of proteinuria occurred in two and partial remission in the other two patients whereas renal function improved or remained stable. During treatment and the follow-up period (18-60 months) no severe infectious complications were observed. Our data suggest that the combination of plasmapheresis and rituximab is an acceptable treatment in patients with post-transplantation recurrent FSGS.
机译：肾同种异体移植中复发性局灶性节段性肾小球硬化症（FSGS）的治疗主要基于病例报告。单独使用血浆置换术（基于其在儿童中的有效性）在成人中似乎效果较差，反应率<40％。最近，抗CD20单克隆嵌合抗体利妥昔单抗在抗血浆置换术复发性FSGS中作为抢救疗法显示出令人鼓舞的结果。但是，利妥昔单抗给药后，反应是可变的，通常缓慢，因此被忽视。我们报道了肾移植术后成功结合血浆置换术和利妥昔单抗治疗的一系列四例复发性FSGS。蛋白尿的完全缓解发生在两名患者中，部分缓解在其他两名患者中，而肾功能改善或保持稳定。在治疗和随访期间（18-60个月），未观察到严重的感染并发症。我们的数据表明，血浆置换术和利妥昔单抗的组合是移植后复发性FSGS患者的可接受治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号